ALLMedicine™ Lymphomas Center

Mar 28th, 2023 - Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune...

Mar 25th, 2023 - Primary central nervous system lymphoma (PCNSL) is rare, especially lymphoma arising in the fourth ventricle. Only a few cases have been reported. We report a case of fourth ventricular lymphoma and review the relevant literature. Characterizing t...

Mar 25th, 2023 - MicroRNAs (miRNAs) are small non coding RNAs responsible for posttranscriptional regulation of gene expression. Even though almost 2000 precursors have been described so far, additional miRNAs are still being discovered in normal as well as malign...

Mar 24th, 2023 - What is your outlook on the role of upfront autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL)? Dr. Barrientos: Most of the data that we have for upfront ASCT for young patients in frontline therapy come from the e.

Mar 24th, 2023 - Chimeric antigen receptor (CAR) T-cell therapy is currently approved for the treatment of B-cell non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia. Prolonged hematological toxicity is an emergent concern following CAR T cells and occur...

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Jan 9th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...

Mar 23rd, 2023 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...

Mar 23rd, 2023 - Single center, two-parts pilot, prospective study to assess the role of molecular tumor profiling in supporting patient enrollment in early phase clinical trials. Part A: patients with solid tumors or lymphomas (n=40) who are potential candidates ...

Mar 20th, 2023 - Patients in this study will receive nivolumab in combination with the standard of care dose-adjusted EPOCH (etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide) for six 21 day cycles. Patients will then have an autologous stem cell t...

Mar 20th, 2023 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

Mar 20th, 2023 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

Mar 24th, 2023 - What is your outlook on the role of upfront autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL)? Dr. Barrientos: Most of the data that we have for upfront ASCT for young patients in frontline therapy come from the e.

Mar 23rd, 2023 - Key clinical point: Compared with mild atopic dermatitis (AD), severe AD results in an increased risk for overall morbidity. Major finding: Patients with severe vs mild AD had a significantly increased risk for other dermatitis, extragenital herpe.

Mar 9th, 2023 - How the successful use of pembrolizumab (Keytruda) for former President Jimmy Carter's metastatic melanoma put "immunotherapy on the map." (Washington Post) A study of molecular changes observed in the breast tissue of transgender men undergoing a...

Mar 1st, 2023 - The Diagnosis: Plasmablastic Lymphoma A punch biopsy of one of the leg nodules with hematoxylin and eosin staining revealed sheets of medium to large cells with plasmacytic differentiation (Figure, A and B). Immunohistochemistry showed CD79, epith.

Mar 1st, 2023 - Mantle cell lymphoma (MCL) has served as a paradigm of progress among the non-Hodgkin lymphomas over the past 30 years. It was originally defined within the Kiel classification as centrocytic lymphoma, then renamed MCL once the characteristic tran.